Skip to main content
Premium Trial:

Request an Annual Quote

Dicerna Closes $25M Series B

Premium

Dicerna Pharmaceuticals said that it has closed a $25 million Series B round of financing, which will provide the company with the money needed to advance its lead oncology drug-development program, as well as other pipeline efforts.

Dicerna said it would also use the funds to further develop its delivery technologies.

The round was led by a new investor, Domain Associates, and included existing investors Oxford Bioscience Partners, Skyline Ventures, and Abingworth.

Dicerna first disclosed that it was planning the Series B round to Gene Silencing News in May (GSN 5/13/2010).

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.